Stock Analysis
Stoke Therapeutics, Inc. (STOK) Stock Analysis
Stoke Therapeutics, Inc. (STOK) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Stoke Therapeutics, Inc. (STOK) currently has an AIQ Score of 42/100, indicating a bearish setup. Risk is the strongest factor at 59/100. Value is the weakest current factor at 22/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
STOK at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $26.68 |
| AIQ Score | 42/100 |
| Overall View | Bearish |
| Technical Analysis Consensus | Buy |
| Market Cap | $1.82B |
| P/E Ratio (TTM) | -7.04 |
| Forward P/E | — |
| EPS (Q3 FY2026) | -$1.08 |
| Revenue (Q3 FY2026) | $11.26M |
| Dividend Yield (TTM) | 0.00% |
| Beta | 0.96 |
| Volume | 420.23K |
| 52-week range | $22.05-$40.22 |
| RSI 14 | 51.32 |
| 50-Day SMA | $26.45 |
| 200-Day SMA | $30.79 |
| Analyst Price Target | $43.00 |
| Next Earnings | Mar 15, 2027 |
STOKStoke Therapeutics, Inc.
Healthcare / Biotechnology
Low Priority
Relative Laggard
Latest quote
- Momentum47
- Value22
- Quality42
- Risk resilience59
- Sentiment—
STOK Stock Analysis Summary
Stoke Therapeutics, Inc. (STOK) currently has an AIQ Score of 42/100, indicating a bearish setup. Risk resilience is the strongest factor at 59/100. Value is the weakest current factor at 22/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a bearish regime, STOK has AIQ Score of 42/100 with Risk resilience base of 59/100 and fading Value at 22/100. Wait for component alignment before adding exposure.
Risk resilience (59/100) leads while Value (22/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · 1.83% stock move · STOK classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is STOK Bullish or Bearish Right Now?
STOK currently has a bearish overall setup. Risk Resilience is the strongest factor at 59/100, while Value is weakest at 22/100. The current evidence suggests a bearish setup.
- - Price is +0.86% above its 50-day SMA.
- - Analyst target implies +61.17% upside from the latest quote.
- - Technical consensus has more buy votes than sell votes (25 vs 11).
- - Value is the current constraint at 22/100.
- - Momentum is weak at 47/100.
- - Price is -13.34% below its 200-day SMA.
Current Consensus
STOK's Technical Analysis Consensus is currently Buy, with 25 buy, 10 neutral, and 11 sell votes. STOK's 14-day RSI is 51.32, which places the stock in a neutral momentum range. STOK's beta is 0.96, indicating market sensitivity broadly in line with the market.
What Changed in STOK?
The largest recent change in STOK is Momentum moving up by 6.0 points over the available 7-day comparison window. Risk Resilience remains the strongest visible factor.
What Would Change the STOK Outlook?
The current bearish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
STOK Decision Framework
Public evidence layers, setup checks, and risk context for Stoke Therapeutics, Inc..
Stoke Therapeutics, Inc. (STOK) Stock Analysis
Stoke Therapeutics, Inc. has an AIQ Score of 42/100 in a Bearish regime. Risk is strongest at 59/100. Beta is 0.96, close to market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | STOK is in a Bearish AIQ regime with score 42/100. |
| Signal Conflict | The primary conflict is that risk leads at 59/100 while value lags at 22/100. |
| Factor Evidence | Momentum 47/100 · Value 22/100 · Quality 42/100 · Risk 59/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Risk is the strongest factor at 59/100.
Momentum is 47/100 and RSI (14) is 51.3.
STOK is in a Bearish regime at 42/100.
Risk factor is 59/100 with beta 0.96 and annual volatility 53.19%.
Current conflict: risk leads at 59/100 while value lags at 22/100.
STOK Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
STOK Fundamentals
STOK valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
STOK Technical Analysis
STOK technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
STOK Stock Catalysts
Track STOK earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
STOK Dividend Analysis
STOK dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
STOK Financial Data
STOK revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
STOK Risk Analysis
STOK volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
STOK Stock News
STOK stock news, market tone, recent headlines, and catalyst context.
STOK vs Biotechnology Peers
Current peer cohort: STOK · SYRE · TARS · TGTX · TNGX. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| STOK Current stock | 42/100 | 22/100 | 47/100 | 59/100 | 0.23 | 53.19% | Current |
| SYRE Spyre Therapeutics, Inc. | 64/100 | 44/100 | 81/100 | 53/100 | 2.57 | 66.66% | STOK vs SYRE |
| TARS Tarsus Pharmaceuticals, Inc. | 65/100 | 75/100 | 76/100 | 59/100 | 0.36 | 45.02% | STOK vs TARS |
| TGTX TG Therapeutics, Inc. | 76/100 | 65/100 | 93/100 | 63/100 | 1.74 | 46.06% | STOK vs TGTX |
| TNGX Tango Therapeutics, Inc. | 61/100 | — | 60/100 | 38/100 | 1.61 | 101.07% | STOK vs TNGX |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
Also for STOK: historical return with reinvested dividends and stock average calculator for several buys.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Nov 16, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Sep 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching STOK
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for STOK
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
STOK Stock FAQ
What is STOK stock price today?
Stoke Therapeutics, Inc.'s current stock price is $26.68. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is STOK bullish or bearish right now?
STOK's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is STOK's market cap?
STOK's market cap is $1.82B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is STOK's current P/E ratio?
STOK's current P/E ratio is -7.04 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is STOK's RSI?
STOK's 14-day RSI is 51.32 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is STOK above its 50-day and 200-day moving averages?
STOK is 0.86% from its 50-day SMA and -13.34% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is STOK's next earnings date?
STOK's next earnings date is currently listed as Mar 15, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does STOK pay a dividend?
STOK's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.